Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter
MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click: www.youtube.com/msviewsandnews
Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, September 12, 2016
Multiple Sclerosis: More Good News on Siponimod
Click here to receive MS news via e-mail
Sep 9, 2016
Patients with relapsing-remitting multiple sclerosis (RRMS) receiving siponimod treatment for 24 months had low disease activity and showed no new safety signals, according to an extension of the phase 2 BAF312 on MRI Lesion Given Once Daily (BOLD) study. The extension was conducted by Ludwig Kappos, MD, of the Neurologic Clinic and Proclinic, in the Department of Medicine at the University Hospital Basel in Switzerland, and colleagues, and was published in JAMA Neurology in July, 2016. -
This study extension was dose-blinded and randomized, and the main outcomes included a safety assessment and efficacy measures. The researchers say, “Safety assessment included blood tests, documentation of adverse events at regular scheduled visits and Holter monitoring; key efficacy measures were annualized relapse rate and magnetic resonance imaging lesion activity.”
MS Views and News
Providing educational information, resources and services for those affected by MS